2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Plasma cell
2
Conditions
Breast Neoplasms
1334
Neoplasms
1111
Carcinoma, Non-Small-Cell Lung
923
Prostatic Neoplasms
755
Colorectal Neoplasms
653
Lung Neoplasms
626
Neoplasm Metastasis
476
Multiple Myeloma
449
Leukemia, Myeloid, Acute
441
Pancreatic Neoplasms
394
Ovarian Neoplasms
390
Melanoma
350
Carcinoma, Hepatocellular
311
Brain Neoplasms
293
Recurrence
289
Squamous Cell Carcinoma of Head and Neck
287
Glioblastoma
263
Head and Neck Neoplasms
256
Stomach Neoplasms
255
Precursor Cell Lymphoblastic Leukemia-Lymphoma
242
Carcinoma, Renal Cell
241
Lymphoma
237
Triple Negative Breast Neoplasms
234
Endometrial Neoplasms
223
Hematologic Neoplasms
220
Uterine Cervical Neoplasms
217
Urinary Bladder Neoplasms
213
Glioma
208
Lymphoma, Non-Hodgkin
206
Sarcoma
204
Interventions
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Amyloid Neuropathies, Familial
×
90 days
×
Clear all
NCT05184088
2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3
Completed
244 enrolled
NCT03431896
2026-03-12
MED-hATTR
The Cleveland Clinic
Completed
37 enrolled